| |
| |
|
| Insider
Information: |
Yossi Maimon |
| Relationship: |
CFO, Secretary and Tre... |
| City: |
Carmiel, Israel |
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
10,000 |
|
|
Indirect Shares
|
185,000 |
|
|
| Direct
Value |
$2,646 |
|
|
|
Indirect Value
|
$48,951 |
|
|
| Total
Shares |
195,000 |
|
|
| Total
Value |
$51,597 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Protalix Biotherapeutics |
PLX |
Vice President & CFO |
2015-12-14 |
10,000 |
2015-12-14 |
185,000 |
Premium* |
|
|
Ayala Pharmaceuticals, Inc. |
AYLA |
CFO, Secretary and Tre... |
2023-01-19 |
0 |
2020-05-07 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
33 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 2
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| AYLA |
Ayala Pharmaceuticals, In... |
CFO, Secretary & Treasurer |
• – – |
2020-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
11,352 |
11,352 |
0 |
- |
|
| AYLA |
Ayala Pharmaceuticals, In... |
CFO, Secretary & Treasurer |
• – – |
2021-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
8,520 |
19,872 |
0 |
- |
|
| AYLA |
Ayala Pharmaceuticals, In... |
CFO, Secretary & Treasurer |
• – – |
2022-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
69,872 |
0 |
- |
|
| AYLA |
Ayala Pharmaceuticals, In... |
CFO, Secretary and Treasurer |
• • – |
2023-01-19 |
4 |
D |
$0.00 |
$0 |
D/D |
(69,872) |
0 |
0 |
- |
|
| PLX |
Protalix Biotherapeutics |
VP, Chief Financial Officer |
• – – |
2008-02-22 |
4 |
D |
$3.20 |
$83,763 |
I/I |
(26,176) |
60,000 |
0 |
- |
|
| PLX |
Protalix Biotherapeutics |
VP, Chief Financial Officer |
• – – |
2008-02-22 |
4 |
OE |
$0.97 |
$83,763 |
I/I |
86,176 |
86,176 |
0 |
- |
|
| PLX |
Protalix Biotherapeutics |
VP, Chief Financial Officer |
• – – |
2008-02-25 |
4 |
S |
$3.18 |
$105,761 |
I/I |
(33,300) |
26,700 |
0 |
- |
|
| PLX |
Protalix Biotherapeutics |
VP, Chief Financial Officer |
• – – |
2009-03-11 |
4 |
S |
$2.30 |
$20,353 |
I/I |
(8,849) |
0 |
0 |
- |
|
| PLX |
Protalix Biotherapeutics |
VP, Chief Financial Officer |
• – – |
2009-03-12 |
4 |
S |
$2.22 |
$71,575 |
I/I |
(32,241) |
0 |
0 |
- |
|
| PLX |
Protalix Biotherapeutics |
VP, Chief Financial Officer |
• – – |
2009-03-13 |
4 |
D |
$2.16 |
$38,686 |
I/I |
(17,910) |
0 |
0 |
- |
|
| PLX |
Protalix Biotherapeutics |
VP, Chief Financial Officer |
• – – |
2009-03-13 |
4 |
OE |
$0.97 |
$38,686 |
I/I |
39,800 |
0 |
0 |
- |
|
| PLX |
Protalix Biotherapeutics |
VP, Chief Financial Officer |
• – – |
2009-03-13 |
4 |
S |
$2.23 |
$16,725 |
I/I |
(7,500) |
0 |
0 |
- |
|
| PLX |
Protalix Biotherapeutics |
VP, Chief Financial Officer |
• – – |
2009-05-18 |
4 |
S |
$4.00 |
$120,000 |
I/I |
(30,000) |
0 |
0 |
- |
|
| PLX |
Protalix Biotherapeutics |
VP, Chief Financial Officer |
• – – |
2009-05-18 |
4 |
D |
$3.79 |
$39,219 |
I/I |
(10,348) |
30,000 |
0 |
- |
|
| PLX |
Protalix Biotherapeutics |
VP, Chief Financial Officer |
• – – |
2009-05-18 |
4 |
OE |
$0.97 |
$39,218 |
I/I |
40,348 |
40,348 |
0 |
- |
|
| PLX |
Protalix Biotherapeutics |
VP, Chief Financial Officer |
• – – |
2009-07-06 |
4 |
AS |
$5.13 |
$205,200 |
I/I |
(40,000) |
0 |
0 |
- |
|
| PLX |
Protalix Biotherapeutics |
VP, Chief Financial Officer |
• – – |
2009-07-07 |
4 |
D |
$4.95 |
$60,474 |
I/I |
(12,217) |
0 |
0 |
- |
|
| PLX |
Protalix Biotherapeutics |
VP, Chief Financial Officer |
• – – |
2009-07-07 |
4 |
OE |
$0.97 |
$60,475 |
I/I |
62,217 |
0 |
0 |
- |
|
| PLX |
Protalix Biotherapeutics |
VP, Chief Financial Officer |
• – – |
2009-07-07 |
4 |
AS |
$5.01 |
$50,100 |
I/I |
(10,000) |
0 |
0 |
- |
|
| PLX |
Protalix Biotherapeutics |
VP, Chief Financial Officer |
• – – |
2009-10-15 |
4 |
AS |
$9.50 |
$1,042,150 |
I/I |
(109,700) |
0 |
0 |
- |
|
| PLX |
Protalix Biotherapeutics |
VP, Chief Financial Officer |
• – – |
2009-10-16 |
4 |
D |
$9.21 |
$162,999 |
I/I |
(17,698) |
0 |
0 |
- |
|
| PLX |
Protalix Biotherapeutics |
VP, Chief Financial Officer |
• – – |
2009-10-16 |
4 |
OE |
$0.97 |
$163,002 |
I/I |
167,698 |
0 |
0 |
- |
|
| PLX |
Protalix Biotherapeutics |
VP, Chief Financial Officer |
• – – |
2009-10-16 |
4 |
AS |
$9.35 |
$376,805 |
I/I |
(40,300) |
0 |
0 |
- |
|
| PLX |
Protalix Biotherapeutics |
VP, Chief Financial Officer |
• – – |
2010-09-03 |
4 |
AS |
$8.00 |
$308,000 |
I/I |
(38,500) |
0 |
0 |
- |
|
| PLX |
Protalix Biotherapeutics |
VP, Chief Financial Officer |
• – – |
2010-09-07 |
4 |
OE |
$0.97 |
$68,040 |
I/I |
70,000 |
0 |
0 |
- |
|
33 Records found
|
|
Page 1 of 2 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
